Alector will host a conference call on August 7, 2025, to discuss Q2 results and business updates.
Quiver AI Summary
Alector, Inc., a biotechnology company focused on neurodegenerative disease therapies, announced it will hold a conference call and webcast on August 7, 2025, at 4:30 p.m. ET to discuss its second quarter results and provide a mid-year business update. The event will include insights from Dr. Ryan Darby, a neurology expert from Vanderbilt University, who will address the unmet need in frontotemporal dementia. A press release detailing the company's financial results will be shared before the call. Participants can join the call via webcast or phone after registration, with a replay available afterward. Alector is developing therapies for diseases like Alzheimer’s and Parkinson’s, using its proprietary blood-brain barrier platform to enhance drug delivery and efficacy.
Potential Positives
- Alector will provide a comprehensive mid-year business update during the conference call, which enhances transparency and keeps investors informed about the company's progress.
- The involvement of Dr. Ryan Darby, an expert in the field, highlights Alector's commitment to addressing unmet medical needs in neurodegenerative diseases, potentially increasing investor confidence.
- The announcement of a proprietary blood-brain barrier platform, Alector Brain Carrier (ABC), underscores the company's innovation and could improve the efficacy of its therapies, which may lead to better patient outcomes and market potential.
- The press release indicates that Alector is actively advancing its product pipeline, suggesting ongoing progress in developing therapies for serious conditions like frontotemporal dementia, Alzheimer's disease, and Parkinson's disease.
Potential Negatives
- None
FAQ
What is the date and time of Alector's conference call?
Alector's conference call will be held on August 7, 2025, at 4:30 p.m. ET.
Who will speak during the conference call?
Dr. Ryan Darby will speak about the unmet need in frontotemporal dementia during the call.
How can I access the webcast of the conference call?
The webcast can be accessed live on Alector’s investor relations website on the event date.
How can I participate in the conference call by phone?
Interested parties must register online to receive the dial-in details for phone participation.
What topics will be covered in Alector's mid-year business update?
The update will cover second quarter results and developments in Alector's neurodegenerative therapies.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ALEC Insider Trading Activity
$ALEC insiders have traded $ALEC stock on the open market 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $ALEC stock by insiders over the last 6 months:
- SARA KENKARE-MITRA (President and Head of R&D) has made 0 purchases and 2 sales selling 52,963 shares for an estimated $74,636.
- ARNON ROSENTHAL (Chief Executive Officer) sold 52,087 shares for an estimated $69,713
- MARC GRASSO (Chief Financial Officer) sold 16,488 shares for an estimated $22,067
- KRISTINE YAFFE sold 1,000 shares for an estimated $1,440
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ALEC Hedge Fund Activity
We have seen 64 institutional investors add shares of $ALEC stock to their portfolio, and 66 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. removed 857,045 shares (-9.4%) from their portfolio in Q1 2025, for an estimated $1,054,165
- TD ASSET MANAGEMENT INC added 540,000 shares (+483.3%) to their portfolio in Q2 2025, for an estimated $756,000
- VESTAL POINT CAPITAL, LP added 504,540 shares (+inf%) to their portfolio in Q1 2025, for an estimated $620,584
- VANGUARD GROUP INC added 436,662 shares (+7.8%) to their portfolio in Q1 2025, for an estimated $537,094
- CITADEL ADVISORS LLC removed 419,533 shares (-98.7%) from their portfolio in Q1 2025, for an estimated $516,025
- EVERSEPT PARTNERS, LP added 417,323 shares (+208.6%) to their portfolio in Q1 2025, for an estimated $513,307
- ACADIAN ASSET MANAGEMENT LLC added 410,205 shares (+39.8%) to their portfolio in Q1 2025, for an estimated $504,552
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ALEC Analyst Ratings
Wall Street analysts have issued reports on $ALEC in the last several months. We have seen 2 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- Mizuho issued a "Outperform" rating on 07/28/2025
- HC Wainwright & Co. issued a "Buy" rating on 05/09/2025
- Morgan Stanley issued a "Underweight" rating on 03/07/2025
To track analyst ratings and price targets for $ALEC, check out Quiver Quantitative's $ALEC forecast page.
$ALEC Price Targets
Multiple analysts have issued price targets for $ALEC recently. We have seen 3 analysts offer price targets for $ALEC in the last 6 months, with a median target of $3.5.
Here are some recent targets:
- Graig Suvannavejh from Mizuho set a target price of $3.5 on 07/28/2025
- Andrew Fein from HC Wainwright & Co. set a target price of $10.0 on 05/09/2025
- Sean Laaman from Morgan Stanley set a target price of $1.5 on 03/07/2025
Full Release
SOUTH SAN FRANCISCO, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced it will host a conference call and webcast on Thursday, August 7, 2025, at 4:30 p.m. ET to discuss results for the second quarter ended June 30, 2025, and provide a mid-year business update. The call will feature remarks from Ryan Darby, M.D., Associate Professor of Neurology and Director of the Frontotemporal Dementia Clinic at Vanderbilt University Medical Center, who will speak on the unmet need in frontotemporal dementia. A press release detailing second quarter results will be issued prior to the call.
The event will be webcast live under the investor relations section of Alector’s website at https://investors.alector.com/events-and-presentations/events and following the event a replay will be archived there for 30 days. Interested parties participating by phone will need to register using this online form . After registering for dial-in details, all phone participants will receive an auto-generated e-mail containing a link to the dial-in number along with a personal PIN number to use to access the event by phone.
About Alector
Alector is a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. Leveraging the principles of genetics, immunology, and neuroscience, the company is advancing a portfolio of genetically validated programs that aim to remove toxic proteins, replace missing proteins, and restore immune and nerve cell function. Supported by biomarkers, Alector’s product candidates seek to treat a range of indications, such as frontotemporal dementia, Alzheimer’s disease, and Parkinson's disease. The company is also developing Alector Brain Carrier (ABC), a proprietary blood-brain barrier platform, which is being selectively applied to its next-generation product candidates and research pipeline. ABC aims to enhance the delivery of therapeutics, achieve deeper brain penetration and efficacy at lower doses, and ultimately improve patient outcomes while reducing costs. Alector is headquartered in South San Francisco, California. For more information, please visit
www.alector.com
.
Alector Contacts:
Alector
Katie Hogan
202-549-0557
[email protected]
Argot Partners (media)
David Rosen
646-461-6387
[email protected]
Argot Partners (investors)
Laura Perry
212-600-1902
[email protected]
